China: CFDA Solicits Comments On Drug Registration Rules

The China Food and Drug Administration ("CFDA") recently published long-awaited and comprehensive revisions ("Revisions") to the Drug Registration Rules ("DRR"). The Revisions are now open to public comments until August 26, 2016. Since the DRR is the most important regulation for seeking approval of drugs in China, the pharmaceutical industry is advised to review the Revisions carefully and offer feedback on proposed changes.

The Revisions are said to be a response to the State Council's 2015 announcement (See our Alert dated August 21, 2015) on the reform of the drug and device approval system. As a result, the Revisions contain some of the State Council's requested reforms, including simplifying the drug approval process and imposing severe penalties on false data submitted during drug registration.

Overall, key changes proposed in the Revisions can be divided into the following four categories:

1. Changes that may affect Clinical Trials

  • Remove explicit reference to international multicenter studies: Unlike the DRR, the Revisions do not distinguish an international multicenter study from a drug registration study. The China arm of an international multicenter study, if the data of which will eventually be used for applying the marketing approval in China, must be approved by the CFDA in advance. Companies can include China in any stage of the drug development process when conducting an international multicenter study, rather than having to wait until Phase 2 of the clinical study program.
  • Remove the validity term of clinical trial approval: The Revisions would remove the current DRR requirement that a clinical trial must be launched within three years from the approval date. The Revisions do, however, propose that a clinical trial approval will become invalid if the clinical hold issue can't be resolved for more than 18 months.
  • Add procedures for removing a clinical hold: The Revisions propose that, if a suspended clinical trial can resolve the clinical hold issues, the drug applicant must obtain an ethics committee ("EC") approval first, and then submit a written application regarding the removal of clinical hold to the CFDA. The Revisions also add that both the EC and the principal investigator may request to suspend or terminate an ongoing trial, if there are any unexpected serious adverse events.

2. Changes that may affect Drug Regulatory Approval Process

  • Abolish the statutory technical review time limit: Under the DRR, the Center of Drug Evaluation ("CDE") must complete the technical review within a statutory timeline. The Revisions, however, explicitly exclude the technical review timeline from the entire drug registration timeline, as well as the inspection and testing timeline. Furthermore, at the beginning of each year, the Revisions specify the CDE would need to publish a statistical report regarding the technical review, the on-site inspection and registration testing timeline of the preceding calendar year. In addition, the CDE would provide an estimate of the technical review timeline at different stages for the current year.
  • Prohibit any separate API marketing application: Under the Revisions, an active pharmaceutical ingredient ("API") marketing application would have to be bundled with a drug product marketing application. In other words, the CFDA would reject any API marketing application that is submitted separately without identifying the relevant drug product marketing application.
  • Simplify the license renewal procedure: According to the Revisions, a drug approval holder must submit the renewal application no later than three months before the drug registration approval expires. If the CFDA fails to reach a decision prior to the expiration date, the renewal application will be automatically approved.
  • Limit the scope of changes to pending applications: There is no available procedure for making changes to approved clinical trials in the current DRR. In its 2013 draft amendments (See our Alert dated November 18, 2013) to the DRR, the CFDA had proposed that an applicant for an investigational new drug approval could make changes to the approval holder, the manufacturing process, the manufacturing site and the product specification by filing a supplementary application. The Revisions, in contrast, specify that an applicant can make only non-significant changes during the clinical trial process—although the Revisions do not define "non-significant changes." In terms of reviewing the marketing approval application, the Revisions further require that any changes in the conditions of manufacturing, quality control and use must be made through a new application, rather than a supplementary application.

3. Changes that may affect the Administrative Exclusivity

  • Eliminate the linkage between patent protection and the drug approval process: In the current DRR, any applicant must submit a drug application two years prior to the expiration date of any third-party patent in China, and the CFDA cannot approve an application before the patent expires. Under the Revisions, any applicant can submit a marketing authorization application, regardless of the existence of third-party patents. This change is proposed in response to the Bolar Exemption provisions in the PRC Patent Law.
  • Limit the exclusivity scope during the new drug monitoring period: The current DRR prohibits the CFDA from accepting any applications for clinical study authorizations on a new drug during its monitoring period. However, the Revisions limit the exclusivity by only prohibiting the CFDA from accepting any marketing approval application of the same drug. In other words, the Revisions would allow the CFDA to accept and review other clinical trial authorization applications of the same drug during the monitoring period. Additionally, the Revisions would allow the CFDA to approve a third-party marketing approval application during the monitoring period, but only if the new drug has not yet been placed in the market within two years from the start of the monitoring period.
  • Grant administrative exclusivity to approved TCM new drugs: Currently, a traditional Chinese medicine ("TCM") manufacturer can apply for a TCM protection certificate separately from the drug registration procedure. If any TCM obtains a protection status designation, then only the TCM protection certificate holder can manufacture the TCM during the protection period. The Revisions propose that any TCM new drug will be granted a protection designation automatically upon the approval date of such new drug. At the same time, the CFDA will refuse to accept any marketing approval application of the same TCM. 

4. Changes that may affect the Drug Applicant's Rights and Obligations

  • Specify the qualified applicant for CADN application: Any new Chinese Approved Drug Names ("CADN") must be approved by Chinese Pharmacopoeia Commission ("CPC"). However, the Revisions specify that CDE, not the drug applicant, shall submit the CADN proposal regarding the new drug to CPC. Once CPC makes a determination regarding the new CADN, it will notify only the CDE.
  • Impose evaluation requirement for contract research or manufacturing organizations: According to the Revisions, if a drug applicant contracts a third party to provide drug development services or produce drug samples, the drug applicant must conduct an evaluation of the service provider's quality system by itself or another evaluation agency.
  • Outsource drug registration testing to private testing institutions: Currently, only the National Institute for Food and Drug Control and its provincial counterparts can conduct the drug registration tests. The Revisions allow qualified private testing institutions to handle drug registration tests.
  • Appoint a dedicated person for regulatory filings: The Revisions ask the applicants for a dedicated regulatory specialist to handle the registration applications and to communicate with the CFDA on behalf of the applicants. If the CFDA discovers any misrepresentation or falsification of data or samples in the dossiers, the responsible regulatory specialist will be blacklisted.

The Revisions unveiled many material changes to the drug registration system and will significantly impact the future business strategy of pharmaceutical companies in China. It remains unclear whether these changes will be adopted. We recommend that pharmaceutical companies closely monitor the progress of the Revisions and propose their comments by the deadline.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
CMS Cameron McKenna Nabarro Olswang LLP
CMS Cameron McKenna Nabarro Olswang LLP
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
CMS Cameron McKenna Nabarro Olswang LLP
CMS Cameron McKenna Nabarro Olswang LLP
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions